396 results on '"Moreaux J"'
Search Results
2. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness
3. Transient loss of Polycomb components induces an epigenetic cancer fate
4. Tumor-associated neutrophils correlate with poor prognosis in diffuse large B-cell lymphoma patients
5. P843: METABOLOMIC CHARACTERIZATION OF HUMAN MULTIPLE MYELOMA CELL LINE TO STUDY TUMOR RESISTANCE TO DIFFERENT CLASSES OF THERAPEUTIC AGENTS
6. P844: CHARACTERIZATION OF MULTIPLE MYELOMA CELL LINES WITH ACQUIRED-RESISTANCE TO PROTEASOME INHIBITORS HIGHLIGHTS A LINK BETWEEN RESISTANCE AND METABOLIC DEREGULATION
7. RECQ1 helicase is involved in replication stress survival and drug resistance in multiple myeloma
8. IRONOMYCIN KILLS DIFFUSE LARGE B‐CELL LYMPHOMA CELLS BY TARGETING CELLULAR IRON HOMEOSTASIS
9. Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins
10. Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis
11. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma
12. Inhibition of HIF1A signaling by a novel class of sulfonanilides for targeted treatment of multiple myeloma: V935
13. Proliferation Is a Central Independent Prognostic Factor and Target for Personalized and Risk Adapted Treatment in Multiple Myeloma: V644
14. Clinical Use of Gene Expression Based Risk Assessment and Identification of Possible Therapeutic Targets in Multiple Myeloma: V299
15. Osteoclast Gene Expression Profiling in Multiple Myeloma: B577
16. Molecular Classification of Myeloma Cell Lines Is Related to that of Patients with Myeloma: B310
17. Angiogenesis in Multiple Myeloma: Induction by Normal Plasma Cell — and Aberrantly Expressed Genes: B050
18. Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma: B033
19. A Gene Expression-Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma: B034
20. BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells: A167
21. Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis
22. Compte rendu de congrès
23. CeVi: A UNIQUE CRYOPRESERVED HUMAN VIABLE CELL COLLECTION FROM LYMPHOMA PATIENTS, A CALYM INITIATIVE TO ACCELERATE INNOVATION AND ITS TRANSFER TO LYMPHOMA FIELD
24. PF577 TARGETING PROTEIN ARGININE METHYLTRANFERASE PRMT5 IN HIGH-RISK MULTIPLE MYELOMA: A NEW TREATMENT STRATEGY?
25. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell
26. PO-481 Alteration in epigenetic-related genes and histones modifications levels revealed as a potential resistance factor to oxaliplatin in colorectal cancer cells
27. Elective resection for diverticular disease of the sigmoid colon
28. La consommation de tabac, alcool et cannabis chez les adolescents et jeunes adultes atteints de cancer a-t-elle un impact sur l’utilisation hospitalière des traitements antalgiques pendant la période de traitement ?
29. Inhibition of H3K9 methyltransferase as a potent therapeutic target in multiple myeloma
30. Vaccine based immunotherapy as a strategy to bypass drug resistance in multiple myeloma
31. RASSF4 functions as a tumor suppressor in Multiple Myeloma
32. Role of RECQ1 helicase in multiple myeloma drug resistance
33. Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma
34. The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells
35. Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
36. Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma
37. Lecture critique et rédaction médicale scientifique. Comment lire, rédiger et publier une étude clinique ou épidémiologique
38. SULF1 (sulfatase 1)
39. MYEOV (myeloma overexpressed (in a subset of t(11;14) positive multiple myelomas))
40. CCR2 (chemokine (C-C motif) receptor 2)
41. Tableaux de Burt et tableaux de Condorcet associés à un tableau ku dont l'un des deux ensembles I ou J est muni d'une partition
42. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma
43. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines
44. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma
45. Atacicept in relapsed/refractory multiple myeloma or active Waldenström's macroglobulinemia: a phase I study
46. B034 A Gene Expression—Based Proliferation Index as Independent Prognostic Factor in Multiple Myeloma
47. B310 Molecular Classification of Myeloma Cell Lines Is Related to that of Patients with Myeloma
48. A167 BMP6: A Novel Antiangiogenic, Antiproliferative, and Prognostic Factor Expressed by Myeloma Cells
49. B050 Angiogenesis in Multiple Myeloma: Induction by Normal Plasma Cell — and Aberrantly Expressed Genes
50. B033 Aurora-Kinase Inhibition for Tailored Risk-Adapted Treatment of Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.